Progressive multifocal leukoencephalopathy and newer biological agents.

Area of Science:

• Neuroimmunology
• Virology
• Pharmacology

Background:

• Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating brain disease caused by JC virus, typically occurring in immunocompromised individuals.
• Acquired immunodeficiency syndrome (AIDS) has been the most common predisposing factor for PML over the past 30 years.
• The emergence of PML with specific monoclonal antibody therapies has raised safety concerns and offered insights into disease pathogenesis.

Purpose of the Study:

• To review the risk of PML associated with monoclonal antibodies and other pharmacological agents.
• To propose a biologically plausible explanation for the increased PML risk.
• To explore potential strategies for mitigating PML risk.

Main Methods:

• Review of available data on PML risk with various therapeutic agents.
• Analysis of the association between specific drug classes (e.g., monoclonal antibodies) and PML.
• Investigation into the immunological mechanisms underlying PML development.

Main Results:

• Certain monoclonal antibodies, including natalizumab and efalizumab, appear to uniquely predispose patients to PML.
• PML occurrence with other agents like rituximab or mycophenolate mofetil is often associated with pre-existing risk factors for PML.
• The pathogenesis of PML is being elucidated through the study of these drug-associated cases.

Conclusions:

• Monoclonal antibodies and other immunosuppressive drugs necessitate careful risk-benefit assessment regarding PML.
• Understanding the specific mechanisms of immune suppression is crucial for predicting and preventing PML.
• Further research is needed to develop effective strategies for mitigating PML risk in patients undergoing these therapies.